An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Crossover Truncated Four Period Fully Replicate Reference Scaled Average Oral Bioequivalence Study Comparing Relugolix 120 mg Tablets Manufactured By BDR Pharmaceuticals Internationals Pvt Ltd India With Orgovyx (Relugolix) 120 MG Tablets Distributed By Sumitomo Pharma America Inc In Healthy Adult Human Male Subjects Under Fed Conditions - NIL

Start Date01 Jul 2025

Sponsor / Collaborator

BDR Pharmaceuticals International Pvt Ltd.

CTR20244923

/ RecruitingPhase 3

一项在激素敏感性晚期前列腺癌患者中评估QLG1080（瑞卢戈利片）有效性和安全性的多中心研究

[Translation] A multicenter study evaluating the efficacy and safety of QLG1080 (relugolix tablets) in patients with hormone-sensitive advanced prostate cancer

主要研究目的：以血清睾酮持续去势率为主要评价指标，评价QLG1080（瑞卢戈利片）治疗激素敏感性晚期前列腺癌的有效性。次要研究目的：评价QLG1080（瑞卢戈利片）治疗激素敏感性晚期前列腺癌患者的安全性及其他疗效指标。

[Translation]

Main study purpose: To evaluate the effectiveness of QLG1080 (Relugoli tablets) in the treatment of hormone-sensitive advanced prostate cancer, using serum testosterone continuous castration rate as the main evaluation index. Secondary study purpose: To evaluate the safety and other efficacy indicators of QLG1080 (Relugoli tablets) in the treatment of hormone-sensitive advanced prostate cancer patients.

Start Date24 Feb 2025

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

NCT06837896

/ Not yet recruitingPhase 3

A Multicenter Study Evaluating the Efficacy and Safety of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.

Start Date01 Feb 2025

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Relugolix

100 Translational Medicine associated with Relugolix

100 Patents (Medical) associated with Relugolix

213

Literatures (Medical) associated with Relugolix

01 Mar 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer

Article

Author: Moraca, Federica ; Napolitano, Fabiana ; D'Aria, Federica ; Pagano, Bruno ; Amato, Jussara ; Landolfi, Laura ; Castellano, Giuliano ; Catalanotti, Bruno ; Di Porzio, Anna ; Malfitano, Anna Maria ; Arciuolo, Valentina ; Marzano, Simona ; Randazzo, Antonio

Breast cancer, a leading cause of cancer-related mortality in women, is characterized by genomic instability and aberrant gene expression, often influenced by noncanonical nucleic acid structures such as G-quadruplexes (G4s). These structures, commonly found in the promoter regions and 5'-untranslated RNA sequences of several oncogenes, play crucial roles in regulating transcription and translation. Stabilizing these G4 structures offers a promising therapeutic strategy for targeting key oncogenic pathways. In this study, we employed a drug repurposing approach to identify FDA-approved drugs capable of binding and stabilizing G4s in breast cancer-related genes. Using ligand-based virtual screening and biophysical methods, we identified several promising compounds, such as azelastine, belotecan, and irinotecan, as effective G4 binders, with significant antiproliferative effects in breast cancer cell lines. Notably, belotecan and irinotecan exhibited a synergistic mechanism, combining G4 stabilization with their established topoisomerase I inhibition activity to enhance cytotoxicity in cancer cells. Our findings support the therapeutic potential of G4 stabilization in breast cancer, validate drug repurposing as an efficient strategy to identify G4-targeting drugs, and highlight how combining G4 stabilization with other established drug activities may improve anticancer efficacy.

01 Mar 2025·FERTILITY AND STERILITY

Inhibition of ovulation and pharmacologic mechanism of action of relugolix combination therapy

Article

Author: Klipping, C ; Arjona Ferreira, J C ; Migoya, E M ; Li, Y ; Wedemeyer, R-S ; Schug, B S ; Draeger, C ; Duijkers, I J M

OBJECTIVE:

To assess the effects of relugolix combination therapy on ovarian function in healthy, ovulatory, premenopausal women.

DESIGN:

This was an open-label, single-cohort, pharmacodynamic, safety and tolerability study consisting of five study periods: a Pre-Treatment Period to confirm ovulatory status, three 28-day treatment periods, and a Post-Treatment Period to assess duration of time required to return to ovulation following treatment discontinuation. Ovarian function was assessed by transvaginal ultrasonography and serum hormone concentrations.

SUBJECTS:

Healthy, premenopausal female participants, 18-35 years of age.

INTERVENTION/EXPOSURE:

Relugolix combination therapy (relugolix 40 mg, with estradiol 1 mg and norethindrone acetate 0.5 mg) was taken orally once daily for 84 days.

MAIN OUTCOME MEASURES:

The primary endpoint was the proportion of women in whom ovulation was inhibited during the entire 84-day treatment period. Secondary endpoints included proportion of women in whom ovulation was inhibited within each treatment period, number of women who fulfilled the Landgren criterion; characterization of follicular diameter, hormone concentrations, and endometrial thickness; time to return to ovulation following treatment discontinuation; proportion of women who returned to ovulation within 36 days following treatment discontinuation; safety and tolerability.

RESULTS:

Seventy women were enrolled in the study, 67 of whom completed treatment. Treatment with relugolix combination therapy inhibited ovulation in 100% of women who completed treatment (95% confidence interval: 94.6, 100.0). Systemic concentrations of luteinizing hormone and follicle-stimulating hormone were suppressed and maintained at low concentrations during treatment, with an absence of a preovulatory luteinizing hormone surge. Median estradiol concentrations across all women were consistently maintained between 36.8 and 39.1 pg/mL (range: 12.1-121.1 pg/mL) during treatment. All individual progesterone concentrations during treatment remained below 1.57 ng/mL (5 nmol/L). Following treatment discontinuation, all women ovulated or initiated menses. The mean time to return to ovulation was 23.5 days. Treatment was generally well tolerated with no safety or tolerability issues identified.

CONCLUSION:

Relugolix combination therapy inhibits ovulation, which, in the context of this study, was achieved within the first cycle following treatment initiation. The rapid and predictable return of ovarian activity and ovulation following treatment discontinuation is advantageous for patients who wish to conceive thereafter.

01 Feb 2025·Pharmacology Research & Perspectives

Transfer of the Oral Gonadotropin‐Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women

Article

Author: Lee, Sarah ; Brimhall, Darin B. ; Yoshida, Kazumasa ; Chen, Yu‐Luan ; Ufer, Mike

ABSTRACT:

Relugolix is an oral gonadotropin‐releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed‐dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h. Pharmacokinetic parameters were determined, including the cumulative amount of relugolix excreted into breast milk to derive the total infant dose. The safety and tolerability of relugolix were also assessed. Eight healthy lactating women were enrolled and completed the study per protocol. Relugolix was safe and well tolerated based on adverse events and other safety data. It was excreted into breast milk with a median time to peak concentration (tmax) of 5.81 h and a geometric mean peak concentration (Cmax) of 15.7 ng/mL, similar to corresponding plasma data from previous clinical studies. The mean cumulative amount of relugolix excreted was 0.0051 mg over 24 h and 0.0067 mg over 120 h, corresponding to 0.0128% and 0.0167% of the maternal dose, respectively. The body weight‐adjusted relative daily infant dose of approximately 0.25% suggests a 400‐fold lower newborn than maternal relugolix exposure. Relevant effects of relugolix on the breastfed child appear unlikely given its limited excretion into breast milk of lactating women but cannot be fully excluded in the absence of infant safety data.

News (Medical) associated with Relugolix

13 Mar 2025

·www.pharmaceutical-technology.com

Gedeon Richter’s once-daily endometriosis pill approved for NHS use

Endometriosis can cause severe pain, heavy periods, fatigue, and fertility issues. Credit: LaylaBird via Getty Images. The UK’s National Institute for Health and Care (NICE) has approved Gedeon Richter’s Ryeqo (relugolix–estradiol–norethisterone), a once-daily oral treatment for endometriosis, for use on the National Health Service (NHS). The drug works by blocking gonadotrophin releasing hormone (GnRH) that contributes to endometriosis while simultaneously providing necessary hormone replacement. Unlike traditional GnRH agonists – such as Takeda’s Prostap (leuprorelin) and AstraZeneca’s Zoladex (goserelin) – which are limited to six months of use, Ryeqo can be taken until menopause. NICE estimates that around 1,000 women per year could benefit from the treatment, which has a list price of £72 per 28-day pack. Helen Knight, director of medicines evaluation at NICE, highlighted the benefits of a pill-based treatment: “Instead of travelling to clinics for injections, there is now a daily tablet that can be taken at home. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects.” Endometriosis, a condition where tissue similar to the womb lining grows outside the uterus, causes severe pain, heavy periods, fatigue and fertility issues. Current treatment options include pain relief, hormonal therapy, and surgery. Ryeqo is now an option for those who have previously undergone medical or surgical treatments but found alternatives like tranexamic acid, hormonal contraceptives, and intrauterine delivery systems ineffective or unsuitable. NICE’s final draft guidance emphasised the need for non-invasive, long-term treatment options for endometriosis symptoms, as there is no cure. Charities, including Endometriosis UK, welcomed the news, but noted that Ryeqo induces a state of “medical menopause” alongside hormone replacement therapy (HRT), meaning it may only be suitable for “a small proportion of the 1.5 million with the disease”. NICE reversed its previous negative stance on the drug after Gedeon Richter provided additional evidence on the drug’s effectiveness and cost-effectiveness. Ryeqo improved endometriosis-associated pain and was well tolerated compared to placebo in the Phase III SPIRIT 1 (NCT03204318) and SPIRIT 2 (NCT03204331) clinical studies, which enrolled over 1,200 women. Beyond the approval of new treatments, Endometriosis UK has called for greater investment in research to find the root cause of the disease, improve management strategies, and to develop a cure. At the Royal Society of Medicine’s Innovation in Women’s Health and Femtech meeting on 3 March 2025, McKinsey partner Anouk Petersen pointed out that despite affecting a similar proportion of the population as diabetes (about 10%), endometriosis receives eight to ten times less funding. A report from McKinsey & Company and the World Economic Forum underscored the economic impact of conditions like endometriosis, finding that while women live longer than men, they spend 25% more of their lives in debilitating health conditions. This has direct productivity consequences, with 60% of the gender health gap occurring during prime working years, contributing to 80% of the economic burden on gross domestic product (GDP). According to GlobalData’s Pharma Intelligence Center, Ryeqo is forecast to generate up to $775m in sales in 2030. GlobalData is the parent company of Pharmaceutical Technology.

Clinical ResultDrug ApprovalPhase 3

13 Mar 2025

·pmlive.com

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Gideon Richter’s Ryeqo (relugolix, estradiol and norethisterone) as the first long-term daily pill for endometriosis. NICE has recommended in final draft guidance that the relugolix combination therapy be used on the NHS in England to treat the symptoms of endometriosis in adults of reproductive age who have had medical or surgical treatment for the chronic condition. The health technology assessment agency’s decision follows an earlier negative recommendation and comes after Gideon provided new evidence on the Ryeqo’s effectiveness and value for money. Affecting approximately 1.5 million women in the UK, endometriosis occurs when tissue similar to the lining of the uterus grows elsewhere in the body. Patients can experience a range of symptoms, including dysmenorrhoea (painful cramping, usually in the lower abdomen), heavy bleeding and pelvic pain. Ryeqo is designed to block the specific hormones that contribute to endometriosis while also providing necessary hormone replacement in a single daily tablet. NICE estimates that around 1,000 patients per year could benefit from the therapy. Helen Knight, director of medicines evaluation at NICE, said Ryeqo “marks a potential step-change in how we manage endometriosis”. She continued: “Instead of travelling to clinics for injections, there is now a daily tablet that can be taken at home. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects.” Among the clinical evidence supporting NICE’s recommendation were positive results from the late-stage SPIRIT programme, in which significantly more patients achieved pain reduction with Ryeqo versus placebo at 24 weeks. In the SPIRIT 1 study, 75% of patients responded to Ryeqo for their dysmenorrhoea compared to 27% in the placebo arm. The same result was seen in SPIRIT 2, with 75% of dysmenorrhoea responders in the Ryeqo cohort compared to 30% for placebo. Additionally, 59% and 66% of patients responded to Ryeqo for their non-menstrual pelvic pain (NMPP) in SPIRIT 1 and 2, respectively, compared to 40% and 43% of those receiving placebo. Positive long-term efficacy data from the SPIRIT open-label extension study, which showed that dysmenorrhoea and NMPP reduction was sustained over two years with Ryeqo treatment, also supported the agency’s decision.

Clinical ResultDrug Approval

29 Jan 2025

·www.prnewswire.com

Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global expertise in product commercialization. She has been instrumental in the development and approval of multiple drugs across several therapeutic areas, including blockbuster medicines like LIPITOR® and CRESTOR®," said Todd Harris, CEO of TYRA. "Adele has a diversified background both as a pharmaceutical executive and board member, with a wealth of knowledge in growing oncology business units. Her experience in launching ORGOVYX® for prostate cancer will be particularly valuable as we plan for late-stage development of TYRA-300 in non-muscle invasive bladder cancer. We look forward to Adele's insights as we advance our precision medicine pipeline and continue to grow TYRA." Most recently, Ms. Gulfo served as Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where she led the commercial and development portfolio for multiple therapeutic areas including oncology, rare disease, urology, CNS and Women's Health. Previously, Ms. Gulfo served as chief commercial and business development officer at Sumitovant Biopharma from 2020 to 2023. Previously, she served as chief commercial development officer at Roivant Sciences, where she was influential in the formation of Sumitovant and in preparations for the launches of key brands, including ORGOVYX® (prostate cancer), GEMTESA (overactive bladder), RETHYMIC (congenital athymia), and MYFEMBREE (women's health). Adele was the president and general manager of Pfizer's $12B+ U.S. primary care business unit, as well as country manager for Pfizer's U.S. Biopharma business, including specialty and oncology business units. Earlier in her career at Pfizer, Adele was instrumental in the development, launch, and commercial success of LIPITOR®, which became the world's best-selling medicine. Prior to Pfizer, Adele held vice president roles within AstraZeneca, including business development and innovation and commercial readiness, as well as the multi-billion-dollar cardiovascular business unit. She oversaw the launch of Crestor® and its growth into a $2 billion medicine. Ms. Gulfo received a BS in biology from Seton Hall University and an MBA in marketing with highest honors from Fairleigh Dickinson University. She studied post-graduate molecular biology at the University of Medicine and Dentistry of New Jersey where she began her career. Ms. Gulfo has been awarded several patents over her career and has extensive public company board experience. Currently, Ms. Gulfo serves on the board of directors of Enpro, a publicly traded industrial engineering firm, and the Innovation Growth Board for Mass General Brigham, the largest hospital-based research enterprise in the United States. "TYRA has great potential to develop best-in-class precision medicines in therapeutic areas like non-muscle invasive bladder cancer and skeletal dysplasia, which represent large market opportunities where innovation is desperately needed," said Ms. Gulfo. "I look forward to partnering with the executive leadership team and other members of the board and leveraging my experience to advance and grow TYRA's pipeline." About Tyra Biosciences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit and engage with us on LinkedIn. Forward-Looking Statements TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the expected advancement of our pipeline and our growth; the potential to develop next-generation precision medicines and their potential to be first-in-class and/or best-in-class; the potential safety and therapeutic benefits of, and market opportunities for, our product candidates; the expected timing and phase of development of TYRA-300; and the potential for SNÅP to develop therapies. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: later developments with the FDA may be inconsistent with prior feedback from the FDA; we are early in our development efforts, have only recently begun testing TYRA-300 and TYRA-200 for oncology in clinical trials and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Amy Conrad [email protected] SOURCE Tyra Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangePhase 2

100 Deals associated with Relugolix

External Link

KEGG	Wiki	ATC	Drug Bank
D10888	Relugolix	L01XX	DB11853

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Prostate Carcinoma	Canada	Sumitomo Pharma Co., Ltd.	10 Oct 2023
Castration-sensitive prostate cancer	European Union	Accord Healthcare SLU	29 Apr 2022
Castration-sensitive prostate cancer	Iceland	Accord Healthcare SLU	29 Apr 2022
Castration-sensitive prostate cancer	Liechtenstein	Accord Healthcare SLU	29 Apr 2022
Castration-sensitive prostate cancer	Norway	Accord Healthcare SLU	29 Apr 2022
Endometriosis	Japan	ASKA Pharmaceutical Co., Ltd.	24 Dec 2021
Prostatic Cancer	United States	Sumitomo Pharma Co., Ltd.	18 Dec 2020
Leiomyoma	Japan	ASKA Pharmaceutical Co., Ltd.	08 Jan 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Prostate Carcinoma	Phase 3	United States	Sumitomo Pharma America, Inc.	31 Jan 2025
Recurrent Prostate Carcinoma	Phase 3	United States	Pfizer Inc.	31 Jan 2025
Menorrhagia	Phase 3	United States	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	Brazil	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	Italy	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	Poland	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	South Africa	Myovant Sciences GmbH	26 Apr 2017
Menorrhagia	Phase 3	United Kingdom	Myovant Sciences GmbH	26 Apr 2017
Uterine Fibroids	Phase 3	United States	Myovant Sciences GmbH	26 Apr 2017
Uterine Fibroids	Phase 3	Brazil	Myovant Sciences GmbH	26 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04666129 (ASCO_GU2025) Manual	Phase 1	Advanced Prostate Carcinoma	24	Relugolix 120 mg + Abiraterone 1000 mg + prednisone 5 mg/methylprednisolone 4 mg (Part 1)	wvjmdhwnnw(gbsncsmawd) = xetylccbgd ykuoatdguq (ypbtrbopfr, 3.2) View more	Positive	13 Feb 2025
				Relugolix 240 mg + Apalutamide 240 mg	wvjmdhwnnw(gbsncsmawd) = zdkqrowlsw ykuoatdguq (ypbtrbopfr, 8.0) View more
ASCO_GU2025	Not Applicable	-	5,274	relugolix (Nonmetastatic Prostate Cancer (nmPC))	duqdljhboe(gaelftmych) = arcnpynxsz pyjrqnakif (qafpwnqhak, ±10 [99]) View more	-	13 Feb 2025
				relugolix (Metastatic Prostate Cancer (mPC))	duqdljhboe(gaelftmych) = nasghbjdxc pyjrqnakif (qafpwnqhak, ±10 [99]) View more
NCT03751124 (CTgov)	Phase 3	Menorrhagia \| Uterine Fibroids	229	Relugolix+E2/NETA (Relugolix Plus E2/NETA (Group A))	cpmmuxkksw = xnhlbimhln fpnyjlwnai (jueuiivcbj, mheadkgzcd - htcnmotvoa) View more	-	25 Jun 2024
				Placebo (Placebo (Group B))	cpmmuxkksw = ohmftnfqey fpnyjlwnai (jueuiivcbj, jfuyvsbcbd - hqnrnqqstm) View more
ASCO2024	Not Applicable	-	267	Relugolix	yzjjknqwoo(lnjlpojdqa) = acute heart failure decompensation, sick sinus syndrome, ventricular tachycardia, and death during treatment ormobfohkh (yzavfqcmip )	-	24 May 2024
NCT05467176 (OPTYX study, ASCO2024)	Not Applicable	Usher Syndromes PSA \| testosterone \| distant metastases	394	Relugolix monotherapy	nzlvpgwvqp(yocjixrwvy) = utnodycowc gcevnqwaov (sjwyoeppph, 238.5) View more	-	24 May 2024
NCT03412890 (CTgov)	Phase 3	Menorrhagia \| Uterine Fibroids	477	Relugolix+E2/NETA (Relugolix Plus E2/NETA (Group A))	qqlvtsyuzn = zjdrcwiwtp ubxdebqqbf (ccttwlxbxp, vfggnocjmk - nyxnxqikwt) View more	-	09 May 2024
				Relugolix+E2/NETA (Relugolix Plus Delayed E2/NETA (Group B))	qqlvtsyuzn = gmlhpmopdp ubxdebqqbf (ccttwlxbxp, ptnsrmdcjg - whuckzpmdz) View more
AUA2024	Not Applicable	Advanced Prostate Carcinoma	-	Leuprolide	eyvsyhorvl(qgwwvvqtkl) = uniaulfvfn yaeguvhtzr (oknlzysiyx )	-	01 May 2024
				Relugolix	eyvsyhorvl(qgwwvvqtkl) = zabfihbbbl yaeguvhtzr (oknlzysiyx )
NCT03103087 \| NCT03049735 \| NCT03412890 (Pubmed \| Am J Obstet Gynecol)	Phase 3	Uterine Fibroids	-	Relugolix combination therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg)	atmvoiowji(trtgloliaw) = 5.7% jkxnzqvhcb (xkuznrpvve ) View more	-	01 Feb 2024
NCT03085095 (HERO, ASCO_GU2024) Manual	Phase 3	Prostatic Cancer	25	Relugolix	tbokxvfxfm(cslneeekpi) = ejsepwacfx xgnohedeeh (fdueyhymsk, 0.67 - 2.5) View more	Positive	25 Jan 2024
HERO study (ASCO_GU2024)	Not Applicable	Advanced Prostate Carcinoma	152	Relugolix	pabyfbyuov(renkiixmtr) = Three pts (2%) had a major adverse cardiovascular event, including one sudden death, one with congestive heart failure, and one with myocardial infarction. Two pts (1%) reported grade 3 fatigue. G3 LFT elevations recorded in 2 pts (1%). No clinical signals of DDI reported. tcnoqkbfky (wbdrlgujlb )	Positive	25 Jan 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis